Clinical trial
proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of…
NCT05590143 · Amsterdam UMC, Other · Active, not recruiting
Key facts
| NCT number | NCT05590143 |
|---|---|
| Title | proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 |
| Official title | Preoperative Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Postoperative Acute Kidney Injury in Cardiac Surgery Patients - a Randomized, Placebo-controlled, Multi-centre, Phase IV Clinical Trial |
| Acronym | MERCURI-2 |
| Lead sponsor | Amsterdam UMC, Other |
| Collaborators | ZonMw: The Netherlands Organisation for Health Research and Development |
| Status | Active, not recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor |
| Intervention type | Drug |
| Interventions | Dapagliflozin 10 MG Oral Tablet [Farxiga], Placebo |
| Enrollment | 784 |
| Start date | Jun 9, 2023 |
| Primary completion | May 14, 2025 |
| Completion | Sep 1, 2025 |
| First posted | Oct 21, 2022 |
| Last update posted | May 18, 2025 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: